KR20230022839A - 조직 저산소증 및 패혈증의 치료에 사용하기 위한 l-트리요오도티로닌(t3)을 포함하는 약학 조성물 (pharmaceutical composition comprising l-triiodothyronine (t3) for use in the treatment of tissue hypoxia and sepsis) - Google Patents

조직 저산소증 및 패혈증의 치료에 사용하기 위한 l-트리요오도티로닌(t3)을 포함하는 약학 조성물 (pharmaceutical composition comprising l-triiodothyronine (t3) for use in the treatment of tissue hypoxia and sepsis) Download PDF

Info

Publication number
KR20230022839A
KR20230022839A KR1020227039203A KR20227039203A KR20230022839A KR 20230022839 A KR20230022839 A KR 20230022839A KR 1020227039203 A KR1020227039203 A KR 1020227039203A KR 20227039203 A KR20227039203 A KR 20227039203A KR 20230022839 A KR20230022839 A KR 20230022839A
Authority
KR
South Korea
Prior art keywords
pharmaceutical composition
sepsis
treatment
triiodothyronine
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227039203A
Other languages
English (en)
Korean (ko)
Inventor
콘스탄티노스 판토스
로다니스 모로지스
Original Assignee
유니-파마 클레온 세티스 파메스티컬 레보라토리스 에스.에이.
세티, 줄리아
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GR20200100200A external-priority patent/GR1010068B/el
Priority claimed from GR20200100695A external-priority patent/GR1010182B/el
Priority claimed from GR20210100216A external-priority patent/GR1010261B/el
Application filed by 유니-파마 클레온 세티스 파메스티컬 레보라토리스 에스.에이., 세티, 줄리아 filed Critical 유니-파마 클레온 세티스 파메스티컬 레보라토리스 에스.에이.
Publication of KR20230022839A publication Critical patent/KR20230022839A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
KR1020227039203A 2020-04-21 2021-04-15 조직 저산소증 및 패혈증의 치료에 사용하기 위한 l-트리요오도티로닌(t3)을 포함하는 약학 조성물 (pharmaceutical composition comprising l-triiodothyronine (t3) for use in the treatment of tissue hypoxia and sepsis) Pending KR20230022839A (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GR20200100200 2020-04-21
GR20200100200A GR1010068B (el) 2020-04-21 2020-04-21 Φαρμακευτικη συνθεση που περιεχει l-τριιωδοθυρονινη (τ3) για χρηση στη θεραπεια ασθενων σε κρισιμη κατασταση με λοιμωξη απο κορωνοϊο
GR20200100695 2020-11-23
GR20200100695A GR1010182B (el) 2020-11-23 2020-11-23 Φαρμακευτικη συνθεση που περιεχει l-τριιωδοθυρονινη (τ3) για χρηση στην αντιμετωπιση της ιστικης υποξιας
GR20210100216 2021-03-29
GR20210100216A GR1010261B (el) 2021-03-29 2021-03-29 Φαρμακευτικη συνθεση που περιεχει l-τριιωδοθυρονινη (τ3) για χρηση στην αντιμετωπιση της φλεγμονωδους αντιδρασης και της δυσλειτουργιας του καρδιαγγειακου συστηματος λογω σηψης
PCT/GR2021/000019 WO2021214497A1 (en) 2020-04-21 2021-04-15 Pharmaceutical composition comprising l-triiodothyronine (t3) for use in the treatment of tissue hypoxemia and sepsis

Publications (1)

Publication Number Publication Date
KR20230022839A true KR20230022839A (ko) 2023-02-16

Family

ID=76197481

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227039203A Pending KR20230022839A (ko) 2020-04-21 2021-04-15 조직 저산소증 및 패혈증의 치료에 사용하기 위한 l-트리요오도티로닌(t3)을 포함하는 약학 조성물 (pharmaceutical composition comprising l-triiodothyronine (t3) for use in the treatment of tissue hypoxia and sepsis)

Country Status (13)

Country Link
US (1) US20230157982A1 (https=)
EP (1) EP4138810A1 (https=)
JP (1) JP2023538984A (https=)
KR (1) KR20230022839A (https=)
CN (1) CN115996710B (https=)
AU (1) AU2021258544A1 (https=)
BR (1) BR112022021250A2 (https=)
CA (1) CA3176106A1 (https=)
GE (2) GEP20247706B (https=)
IL (1) IL297398B1 (https=)
MX (1) MX2022013228A (https=)
WO (1) WO2021214497A1 (https=)
ZA (1) ZA202212502B (https=)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1942995A (en) * 1994-03-15 1995-10-03 K.U. Leuven Research & Development New use of growth hormone
SI3908272T1 (sl) 2019-01-09 2023-07-31 Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A. L-trijodotironin (t3) za uporabo pri omejevanju mikrovaskularne obstrukcije

Also Published As

Publication number Publication date
JP2023538984A (ja) 2023-09-13
IL297398A (en) 2022-12-01
WO2021214497A1 (en) 2021-10-28
ZA202212502B (en) 2024-05-30
MX2022013228A (es) 2022-11-14
GEP20247706B (en) 2024-12-10
CA3176106A1 (en) 2021-10-28
AU2021258544A1 (en) 2022-10-27
IL297398B1 (en) 2026-01-01
BR112022021250A2 (pt) 2022-12-06
EP4138810A1 (en) 2023-03-01
GEAP202416094A (en) 2024-07-10
CN115996710A (zh) 2023-04-21
CN115996710B (zh) 2024-06-28
US20230157982A1 (en) 2023-05-25

Similar Documents

Publication Publication Date Title
Joannidis et al. Prevention of acute kidney injury and protection of renal function in the intensive care unit: expert opinion of the working group for nephrology, ESICM
Brochard et al. An official ATS/ERS/ESICM/SCCM/SRLF statement: prevention and management of acute renal failure in the ICU patient: an international consensus conference in intensive care medicine
Westphal et al. Hydroxyethyl starches: different products–different effects
Niemi et al. Colloid solutions: a clinical update
Kancir et al. The effect of 6% hydroxyethyl starch 130/0.4 on renal function, arterial blood pressure, and vasoactive hormones during radical prostatectomy: a randomized controlled trial
Lee et al. Delineating the relationships among the formation of reactive oxygen species, cell membrane instability and innate autoimmunity in intestinal reperfusion injury
Worcester et al. A test of the hypothesis that oxalate secretion produces proximal tubule crystallization in primary hyperoxaluria type I
Gut et al. Erythropoietin combined with ACE inhibitor prevents heart remodeling in 5/6 nephrectomized rats independently of blood pressure and kidney function
US20220105152A1 (en) Composition for and Method of Treating Hepatic Tissue Injury
Niemi et al. Haemodynamics and Acid-Base Equilibrium after Cardiac Surgery: Comparison of Rapidly Degradable Hydroxythyl Starch Solutions and Albumin
JP7598885B2 (ja) 心血管有害事象のリスクのある対象における鉄欠乏症の処置
KR20230022839A (ko) 조직 저산소증 및 패혈증의 치료에 사용하기 위한 l-트리요오도티로닌(t3)을 포함하는 약학 조성물 (pharmaceutical composition comprising l-triiodothyronine (t3) for use in the treatment of tissue hypoxia and sepsis)
Pachtinger et al. Assessment and treatment of hypovolemic states
KR102776152B1 (ko) 미세혈관 폐쇄를 제한하는 데에 사용하기 위한 l-트리요오도티로닌(t3) (l-triiodothyronine (t3) for use in limiting microvascular obstruction)
US20220062331A1 (en) Treating iron deficiency in subjects at risk of cardiovascular adverse events and iron for the management of atrial fibrillation
HK40088108A (zh) 用於治疗组织缺氧和脓毒症的包含l-三碘甲腺原氨酸(t3)的药物组合物
HK40088108B (zh) 用於治疗组织缺氧和脓毒症的包含l-三碘甲腺原氨酸(t3)的药物组合物
Ishihara Kidney function after the intraoperative use of 6% tetrastarches (HES 130/0.4 and 0.42)
EA048898B1 (ru) Фармацевтическая композиция, содержащая l-трийодтиронин (т3), для применения при лечении тканевой гипоксии и сепсиса
GR1010261B (el) Φαρμακευτικη συνθεση που περιεχει l-τριιωδοθυρονινη (τ3) για χρηση στην αντιμετωπιση της φλεγμονωδους αντιδρασης και της δυσλειτουργιας του καρδιαγγειακου συστηματος λογω σηψης
GR1010182B (el) Φαρμακευτικη συνθεση που περιεχει l-τριιωδοθυρονινη (τ3) για χρηση στην αντιμετωπιση της ιστικης υποξιας
JP2014507468A (ja) 哺乳類の正常血糖を維持するための方法
Kaur et al. Povidone-iodine toxicity in a child posted for laparoscopic removal of hepatic and renal hydatid cysts
Lucas et al. Sex determines cardiac and renal Vulnerability to chronic hemoglobin toxicity
JP7118635B2 (ja) 医薬用組成物

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902